標(biāo)題: Titlebook: Ethics and Governance of Biomedical Research; Theory and Practice Daniel Strech,Marcel Mertz Book 2016 Springer International Publishing Sw [打印本頁] 作者: Halloween 時(shí)間: 2025-3-21 17:37
書目名稱Ethics and Governance of Biomedical Research影響因子(影響力)
書目名稱Ethics and Governance of Biomedical Research影響因子(影響力)學(xué)科排名
書目名稱Ethics and Governance of Biomedical Research網(wǎng)絡(luò)公開度
書目名稱Ethics and Governance of Biomedical Research網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Ethics and Governance of Biomedical Research被引頻次
書目名稱Ethics and Governance of Biomedical Research被引頻次學(xué)科排名
書目名稱Ethics and Governance of Biomedical Research年度引用
書目名稱Ethics and Governance of Biomedical Research年度引用學(xué)科排名
書目名稱Ethics and Governance of Biomedical Research讀者反饋
書目名稱Ethics and Governance of Biomedical Research讀者反饋學(xué)科排名
作者: 搬運(yùn)工 時(shí)間: 2025-3-22 00:17
Research Ethics Forumhttp://image.papertrans.cn/e/image/315997.jpg作者: 小教堂 時(shí)間: 2025-3-22 01:46
978-3-319-80412-5Springer International Publishing Switzerland 2016作者: 涂掉 時(shí)間: 2025-3-22 04:42 作者: Seminar 時(shí)間: 2025-3-22 09:53
https://doi.org/10.1007/978-3-319-28731-7clinical research; cost-effective interventions; medical law; preclinical and clinical research; preclin作者: 藐視 時(shí)間: 2025-3-22 15:49
,Die Grundlagen der Wasserschlo?berechnung,cal research over the past 100 years. “Biomedical research” here is used as a broad term, covering basic, translational, clinical, and post-authorization research towards increasing an understanding of causes, development, and effects of diseases and developing and improving preventive, diagnostic, 作者: 藐視 時(shí)間: 2025-3-22 17:32 作者: consent 時(shí)間: 2025-3-23 00:13
Die Rolle des Teams in der Kundenbetreuung,lthy participants and recent data suggest that some of the healthy participants treat phase I research participation as a form of work. This chapter examines three facets of the shift from research participation as a form of altruism to research participation as a form of work. First, I set out thre作者: cancellous-bone 時(shí)間: 2025-3-23 03:05 作者: corpus-callosum 時(shí)間: 2025-3-23 06:51
Das Weltbild Teilhard de Chardinsironments such as paediatric oncology we should no longer draw sharp distinctions between research and care. Recently, two Dutch protocols for the treatment of children with Acute Lymphoblastic Leukaemia (ALL) have been categorised in two different ways, one as research (ALL-11) and the other as tre作者: 可用 時(shí)間: 2025-3-23 13:37 作者: intrigue 時(shí)間: 2025-3-23 15:35
https://doi.org/10.1007/978-3-658-37774-8ssent has been about the necessary conditions for making a morally significant decision. Some argue that to make a morally significant decision a child has to understand the abstract concept of altruism. Therefore it is crucial to determine at what stage of development this ability arises. Others ar作者: 巨頭 時(shí)間: 2025-3-23 20:33
Einleitung. Fixierung der Probleme,of phase IV studies has led to a greater need to examine the applicable ethics at this stage. Building on our previous work on ethics in phase IV studies, we propose that the following ethical principles are indispensable to implementing ethics in phase IV: (A) When discussing the possibility of wai作者: travail 時(shí)間: 2025-3-23 23:17
Die mathematisch begründeten Ergebnissee Research Ethics Committee of the University of Freiburg, Germany. Published full articles were searched in electronic databases and investigators contacted. Data on study characteristics were extracted from protocols and corresponding publications. We characterized the cohort, quantified its publi作者: 環(huán)形 時(shí)間: 2025-3-24 04:16 作者: 遺留之物 時(shí)間: 2025-3-24 10:07
https://doi.org/10.1007/978-3-322-92512-1te of delivery. Typically, these conditions are discovered over the course of early phase clinical testing. In what follows, we describe a conceptual tool—“ensemble space”—for understanding scientific decision-making in the early phases of clinical development. Briefly, we liken each condition to a 作者: 門閂 時(shí)間: 2025-3-24 12:56 作者: 甜得發(fā)膩 時(shí)間: 2025-3-24 18:36
,Optionsscheine und B?rsentermingesch?fte,d. Three popular interpretations of the minimal risk threshold and the problems they raise when applied in the research context are presented. First, the “risks of daily life” standard and the “routine examinations” standard are addressed. It is argued here that neither of them can provide a satisfa作者: 表示向下 時(shí)間: 2025-3-24 22:30
https://doi.org/10.1007/978-3-642-94447-5ity) is relatively new, and it is taking place at a time when the possibility of undertaking quite detailed genotyping and sequencing is assuming much greater prominence. Although there is much to debate concerning such biobanks, there is broad agreement that their good governance and legitimacy hin作者: cortex 時(shí)間: 2025-3-25 01:01 作者: 字形刻痕 時(shí)間: 2025-3-25 05:03
https://doi.org/10.1007/978-3-663-16168-4 to our translational efforts, they are also highly expensive. To save costs, they are often relocated into developing countries where the protection of study participants is minimal. Such relocation is not necessarily amoral, as those in charge might nevertheless adhere to high ethical standards. H作者: arcane 時(shí)間: 2025-3-25 11:17
Introduction,cal research over the past 100 years. “Biomedical research” here is used as a broad term, covering basic, translational, clinical, and post-authorization research towards increasing an understanding of causes, development, and effects of diseases and developing and improving preventive, diagnostic, 作者: Harpoon 時(shí)間: 2025-3-25 15:23 作者: 可卡 時(shí)間: 2025-3-25 16:30
From Altruists to Workers: What Claims Should Healthy Participants in Phase I Trials Have Against Trlthy participants and recent data suggest that some of the healthy participants treat phase I research participation as a form of work. This chapter examines three facets of the shift from research participation as a form of altruism to research participation as a form of work. First, I set out thre作者: jovial 時(shí)間: 2025-3-25 22:59
Nocebo Effects: The Dilemma of Disclosing Adverse Eventsrug, but a substantial proportion is due to patients being alerted to potential adverse events as part of the informed consent process. Presenting patients with side effects of treatments and interventions can induce so-called “nocebo effects”, which refers to adverse events related to negative expe作者: 向外 時(shí)間: 2025-3-26 03:10
Discriminating Between Research and Care in Paediatric Oncology—Ethical Appraisal of the ALL-10 and ironments such as paediatric oncology we should no longer draw sharp distinctions between research and care. Recently, two Dutch protocols for the treatment of children with Acute Lymphoblastic Leukaemia (ALL) have been categorised in two different ways, one as research (ALL-11) and the other as tre作者: 偶像 時(shí)間: 2025-3-26 07:54 作者: 令人悲傷 時(shí)間: 2025-3-26 11:01
Assent in Paediatric Research and Its Consequencesssent has been about the necessary conditions for making a morally significant decision. Some argue that to make a morally significant decision a child has to understand the abstract concept of altruism. Therefore it is crucial to determine at what stage of development this ability arises. Others ar作者: Latency 時(shí)間: 2025-3-26 14:50
Ethical Principles in Phase IV Studiesof phase IV studies has led to a greater need to examine the applicable ethics at this stage. Building on our previous work on ethics in phase IV studies, we propose that the following ethical principles are indispensable to implementing ethics in phase IV: (A) When discussing the possibility of wai作者: 淺灘 時(shí)間: 2025-3-26 18:02
Fate of Clinical Research Studies After Ethical Approval—Follow-Up of Study Protocols Until Publicate Research Ethics Committee of the University of Freiburg, Germany. Published full articles were searched in electronic databases and investigators contacted. Data on study characteristics were extracted from protocols and corresponding publications. We characterized the cohort, quantified its publi作者: 紀(jì)念 時(shí)間: 2025-3-26 23:37 作者: 淺灘 時(shí)間: 2025-3-27 01:51
Ensemble Space and the Ethics of Clinical Developmentte of delivery. Typically, these conditions are discovered over the course of early phase clinical testing. In what follows, we describe a conceptual tool—“ensemble space”—for understanding scientific decision-making in the early phases of clinical development. Briefly, we liken each condition to a 作者: 離開就切除 時(shí)間: 2025-3-27 08:57 作者: 翻動(dòng) 時(shí)間: 2025-3-27 13:13 作者: persistence 時(shí)間: 2025-3-27 14:00
Big Biobanks: Three Major Governance Challenges and Some Mini-constitutional Responsesity) is relatively new, and it is taking place at a time when the possibility of undertaking quite detailed genotyping and sequencing is assuming much greater prominence. Although there is much to debate concerning such biobanks, there is broad agreement that their good governance and legitimacy hin作者: 開始沒有 時(shí)間: 2025-3-27 20:00
Ethical Dimensions of Dynamic Consent in Data-Intense Biomedical Research—Paradigm Shift, or Red Herthe limitations of traditional informed consent standards, which have been widely perceived as inadequate in large-scale biomedical studies. It uses the approach of a “dynamic consent” as an example, initially in particular in biobanks and genomics, in which participant and patient choices are to be作者: needle 時(shí)間: 2025-3-27 22:48
Using Patent Law to Enforce Ethical Standards: Proposal of a New Patent Requirement to our translational efforts, they are also highly expensive. To save costs, they are often relocated into developing countries where the protection of study participants is minimal. Such relocation is not necessarily amoral, as those in charge might nevertheless adhere to high ethical standards. H作者: 不公開 時(shí)間: 2025-3-28 02:21
Introduction,lenges. It is therefore no surprise that the same stakeholders and guidelines that highlight the need for biomedical research also stress the need to protect research participants and enhance the ethical and scientific quality of research by means of a set of governance tools.作者: 植物學(xué) 時(shí)間: 2025-3-28 09:02
Should Research Ethics Encourage the Production of Cost-Effective Interventions?ffectiveness in research, including the difficulty of predicting effectiveness and cost at the research stage, concerns about limitations in cost-effectiveness analysis, and worries about overly limiting researchers’ freedom. I then consider the advantages and disadvantages of having certain partici作者: innate 時(shí)間: 2025-3-28 14:17 作者: Outmoded 時(shí)間: 2025-3-28 15:00 作者: 巡回 時(shí)間: 2025-3-28 22:39
What Does the Child’s Assent to Research Participation Mean to Parents? Empirical Findings in Paediance to give assent and who should be in charge of it. Our empirical findings indicate that parents want to give children a voice in the decision-making regarding research participation. Even though the child’s competence to rationally understand the research protocol is primarily discussed in the li作者: canvass 時(shí)間: 2025-3-29 00:14
Ethical Principles in Phase IV Studies) The weighing of risks and benefits is a shared responsibility between research ethics committees and sponsors/investigators. (F) In balancing risks and benefits, assuming a therapeutic orientation and applying expected utility theory, the following constraints are in order: the benefit utility tab作者: 拘留 時(shí)間: 2025-3-29 03:36 作者: Nostalgia 時(shí)間: 2025-3-29 09:29
Do Editorial Policies Support Ethical Research? A Thematic Text Analysis of Author Instructions in P performed similarly in this regard. Only every second psychiatry journal adheres to the ICMJE’s recommendation to inform authors about requirements for informed consent and ethics review. Furthermore, we argue that even the ICMJE’s recommendations in this regard are insufficient, at least for ethic作者: 過份 時(shí)間: 2025-3-29 12:05
Ensemble Space and the Ethics of Clinical Developmentand ethical debates in clinical development, such as how aggressively to design early phase studies, when to initiate randomized trials, and reporting requirements for early phase studies. We close by discussing some limitations of the concept of ensemble space.作者: 忙碌 時(shí)間: 2025-3-29 18:34
Towards an Alternative Account for Defining Acceptable Risk in Non-beneficial Paediatric Researchdren in a vaccination programme in the case of an infectious disease, which does not constitute a significant threat to them, can facilitate the definition of this threshold. Although the proposed account shares some of its strong points with those already existing, it does not lead to inconsistenci作者: FEAT 時(shí)間: 2025-3-29 23:11
Big Biobanks: Three Major Governance Challenges and Some Mini-constitutional Responsesarch purposes and projects to be pursued are not specified in advance. Secondly, there is the hot topic of the moment, namely whether biobanks have any responsibility to return individual clinically-significant findings to participants who, because of the longitudinal nature of such research, remain作者: Picks-Disease 時(shí)間: 2025-3-30 00:39 作者: Cocker 時(shí)間: 2025-3-30 05:14 作者: boisterous 時(shí)間: 2025-3-30 09:58 作者: Parameter 時(shí)間: 2025-3-30 13:09
Book 2016tion on core concepts of research ethics is seldom pointless, thoseconfronted with hard moral choices do need more practical and contextualizedreflection on the said issues. This book particularly provides suchcontextualized reflectionsand aims to inform all those who study, conduct,regulate, fund, or participate in biomedical research.作者: faultfinder 時(shí)間: 2025-3-30 20:08 作者: Mnemonics 時(shí)間: 2025-3-30 22:02
Bio- und physioklimatische Fragen,ffectiveness in research, including the difficulty of predicting effectiveness and cost at the research stage, concerns about limitations in cost-effectiveness analysis, and worries about overly limiting researchers’ freedom. I then consider the advantages and disadvantages of having certain partici作者: 斜坡 時(shí)間: 2025-3-31 02:47
Die Rolle des Teams in der Kundenbetreuung, healthy participants that measures the risk level of the trials. Third, once I have found the appropriate “occupational bucket” for phase I work, I briefly examine the implications for contested questions within research ethics, such as the information persons need prior to consent, rights of withd作者: 愉快嗎 時(shí)間: 2025-3-31 07:43 作者: ACRID 時(shí)間: 2025-3-31 12:37 作者: Allure 時(shí)間: 2025-3-31 17:03
Einleitung. Fixierung der Probleme,) The weighing of risks and benefits is a shared responsibility between research ethics committees and sponsors/investigators. (F) In balancing risks and benefits, assuming a therapeutic orientation and applying expected utility theory, the following constraints are in order: the benefit utility tab作者: employor 時(shí)間: 2025-3-31 21:26
Die mathematisch begründeten Ergebnisseudy design was not significantly associated with subsequent publication. Multicentre status, international collaboration, large sample size and commercial or non-commercial funding were positively associated with subsequent publication. Commercial funding was mentioned in 203 (48?%) protocols and in作者: 分解 時(shí)間: 2025-3-31 22:08
https://doi.org/10.1007/978-3-531-91217-2 performed similarly in this regard. Only every second psychiatry journal adheres to the ICMJE’s recommendation to inform authors about requirements for informed consent and ethics review. Furthermore, we argue that even the ICMJE’s recommendations in this regard are insufficient, at least for ethic作者: Interlocking 時(shí)間: 2025-4-1 04:26
https://doi.org/10.1007/978-3-322-92512-1and ethical debates in clinical development, such as how aggressively to design early phase studies, when to initiate randomized trials, and reporting requirements for early phase studies. We close by discussing some limitations of the concept of ensemble space.
